Growth Hormone Peptides Compared: CJC-1295, Ipamorelin & More

The Two Pathways to GH Release

Growth hormone release from the pituitary is controlled by two opposing systems. GHRH (growth hormone-releasing hormone), produced in the hypothalamus, stimulates GH secretion. Somatostatin, also from the hypothalamus, inhibits it. The balance between these two signals determines the pulsatile GH pattern that characterizes healthy physiology.

The five compounds in this comparison exploit this system through two receptor pathways. CJC-1295 and tesamorelin are GHRH analogs that bind the GHRH receptor directly, amplifying the stimulatory signal. Ipamorelin, GHRP-6, and MK-677 are ghrelin mimetics that bind the growth hormone secretagogue receptor (GHSR-1a), a completely separate pathway that both stimulates GH release and suppresses somatostatin’s inhibitory tone.

CJC-1295 DAC: The Long-Acting GHRH Analog

CJC-1295 DAC is a 30-amino-acid synthetic analog of GHRH with a Drug Affinity Complex (DAC) that enables binding to serum albumin. This modification extends the half-life from minutes (native GHRH) to 6-8 days, making it the longest-acting GH secretagogue available.

Teichman and colleagues (JCEM, 2006) demonstrated that a single subcutaneous injection of CJC-1295 DAC produced dose-dependent increases in GH and IGF-1. At the 30 mcg/kg dose, IGF-1 levels increased by 46% after one dose and up to 100% with repeated weekly dosing. The GH elevation was sustained rather than pulsatile, which represents a departure from normal physiology.

The sustained GH elevation is both the advantage and the concern. It means less frequent dosing, but it also means the body does not experience the natural peaks and troughs of GH pulsatility. Whether sustained elevation produces different long-term outcomes than pulsatile release is not well established in clinical data.

Ipamorelin: The Selective Ghrelin Mimetic

Ipamorelin is a pentapeptide ghrelin mimetic that was specifically designed for selectivity. Unlike GHRP-6, which activates the ghrelin receptor broadly and triggers hunger, cortisol, and prolactin alongside GH, ipamorelin produces a clean GH pulse with minimal off-target effects. Anderson and colleagues (European Journal of Endocrinology, 2001) confirmed that ipamorelin did not significantly alter cortisol, prolactin, FSH, LH, or TSH levels at GH-stimulating doses.

The trade-off is a somewhat lower peak GH output compared to GHRP-6. But for research applications where hormonal specificity matters, ipamorelin’s selectivity profile makes it the preferred ghrelin mimetic in most protocols.

Ipamorelin is the only ghrelin mimetic that produces significant GH release without measurably affecting cortisol, prolactin, or appetite at standard dosing.

GHRP-6: The Brute Force Approach

GHRP-6 is the oldest and most potent of the ghrelin mimetics in terms of raw GH output per dose. It produces a strong, rapid GH pulse, but it does so without the selectivity of ipamorelin. GHRP-6 significantly increases appetite (a direct ghrelin receptor effect), raises cortisol levels, and elevates prolactin. These off-target effects limit its utility in contexts where clean GH stimulation is the goal.

For research focused on appetite stimulation alongside GH release, or in models where maximal acute GH output is required regardless of other hormonal changes, GHRP-6 remains relevant. But for most applications, ipamorelin has largely replaced it due to its superior selectivity profile.

Tesamorelin: The Clinical Standard

Tesamorelin is the only FDA-approved growth hormone secretagogue. It is a 44-amino-acid GHRH analog approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Phase 3 trials demonstrated an 18% reduction in visceral adipose tissue, a roughly 80% increase in IGF-1, and improvements in trunk fat and patient-reported body image outcomes.

Tesamorelin produces pulsatile GH release that more closely mimics natural physiology than CJC-1295 DAC’s sustained pattern. Its short half-life of 26 minutes means each injection produces a discrete GH pulse that resolves within hours. This is pharmacologically cleaner but requires daily injections.

MK-677: The Oral Option

MK-677 (ibutamoren) is technically not a peptide but a non-peptide ghrelin mimetic. It activates the same GHSR-1a receptor as ipamorelin and GHRP-6 but is orally bioavailable, making it unique in this comparison. Nass and colleagues (JCEM, 2008) demonstrated sustained IGF-1 increases of 40-60% with daily oral dosing over 12 months in healthy elderly subjects.

Choosing Between Compounds

The selection depends on what trade-offs matter most. For the cleanest GH stimulation with the fewest side effects, ipamorelin stands alone among the ghrelin mimetics. For dosing convenience without injections, MK-677 is the only option. For clinical-grade evidence and FDA approval, tesamorelin has no competition. For maximum IGF-1 elevation with infrequent dosing, CJC-1295 DAC is the leader.

No single compound is best across all parameters. The data presented in the comparison table above should allow researchers to match compound selection to specific research objectives. For detailed profiles on each compound, see our research pages on CJC-1295 DAC, ipamorelin, GHRP-6, tesamorelin, and MK-677.

This article is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before making health-related decisions. Clinical trial data referenced here is sourced from peer-reviewed publications and may not reflect the most current findings.